2.14
price up icon11.46%   0.22
after-market Handel nachbörslich: 2.04 -0.10 -4.67%
loading
Schlusskurs vom Vortag:
$1.92
Offen:
$1.95
24-Stunden-Volumen:
841.60K
Relative Volume:
1.10
Marktkapitalisierung:
$154.77M
Einnahmen:
$6.96M
Nettoeinkommen (Verlust:
$-46.51M
KGV:
-12.47
EPS:
-0.1716
Netto-Cashflow:
$-37.99M
1W Leistung:
+2.39%
1M Leistung:
-15.08%
6M Leistung:
-82.73%
1J Leistung:
-86.01%
1-Tages-Spanne:
Value
$1.93
$2.15
1-Wochen-Bereich:
Value
$1.75
$2.15
52-Wochen-Spanne:
Value
$1.60
$19.05

Perspective Therapeutics Inc Stock (CATX) Company Profile

Name
Firmenname
Perspective Therapeutics Inc
Name
Telefon
509-375-1202
Name
Adresse
350 Hills Street, Suite 106, Richland
Name
Mitarbeiter
91
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-26
Name
Neueste SEC-Einreichungen
Name
CATX's Discussions on Twitter

Vergleichen Sie CATX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Medical Devices icon
CATX
Perspective Therapeutics Inc
2.14 154.77M 6.96M -46.51M -37.99M -0.1716
Medical Devices icon
ABT
Abbott Laboratories
131.73 218.91B 41.95B 13.40B 6.35B 7.65
Medical Devices icon
BSX
Boston Scientific Corp
95.05 139.37B 16.75B 1.85B 2.37B 1.25
Medical Devices icon
SYK
Stryker Corp
348.12 134.90B 22.60B 2.99B 3.49B 7.76
Medical Devices icon
MDT
Medtronic Plc
83.37 106.90B 33.20B 4.26B 5.47B 3.29
Medical Devices icon
EW
Edwards Lifesciences Corp
70.60 41.45B 5.72B 4.17B 259.90M 6.97

Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-13 Eingeleitet H.C. Wainwright Buy
2025-03-07 Eingeleitet Scotiabank Sector Outperform
2024-11-25 Herabstufung BofA Securities Buy → Neutral
2024-10-24 Eingeleitet UBS Buy
2024-10-01 Eingeleitet Wedbush Outperform
2024-09-25 Eingeleitet Truist Buy
2024-07-25 Eingeleitet BofA Securities Buy
2024-05-09 Eingeleitet Cantor Fitzgerald Overweight
Alle ansehen

Perspective Therapeutics Inc Aktie (CATX) Neueste Nachrichten

pulisher
Apr 17, 2025

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results | CATX Stock News - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results - The Manila Times

Apr 17, 2025
pulisher
Apr 17, 2025

Perspective Therapeutics, Inc. to Announce Q1 2025 Financial Results and Business Update on May 12, 2025 - Nasdaq

Apr 17, 2025
pulisher
Apr 17, 2025

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial - Bluefield Daily Telegraph

Apr 17, 2025
pulisher
Apr 14, 2025

Arrowstreet Capital Limited Partnership Has $117,000 Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Apr 14, 2025
pulisher
Apr 12, 2025

KLP Kapitalforvaltning AS Invests $79,000 in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Apr 12, 2025
pulisher
Apr 12, 2025

Truist Financial Issues Pessimistic Forecast for Perspective Therapeutics (NYSE:CATX) Stock Price - MarketBeat

Apr 12, 2025
pulisher
Apr 12, 2025

Perspective Therapeutics (PSTH) Advances Trial for Melanoma Trea - GuruFocus

Apr 12, 2025
pulisher
Apr 12, 2025

Perspective Therapeutics Announces First Patient Dosed with [212 - GuruFocus

Apr 12, 2025
pulisher
Apr 11, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Apr 11, 2025
pulisher
Apr 11, 2025

Perspective Therapeutics Doses First Patient in New Melanoma Trial Cohort With [212Pb]VMT01 Monotherapy - MarketScreener

Apr 11, 2025
pulisher
Apr 11, 2025

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma - The Manila Times

Apr 11, 2025
pulisher
Apr 11, 2025

Perspective Therapeutics Announces First Patient Dosed With Vmt01 Monotherapy In A Phase 1/2A Study Of MC1R-Positive Metastatic Melanoma - MarketScreener

Apr 11, 2025
pulisher
Apr 11, 2025

Breakthrough Melanoma Treatment Shows Promise for Brain Metastasis Patients in Latest Trial - Stock Titan

Apr 11, 2025
pulisher
Apr 09, 2025

Is Now The Time To Invest In Perspective Therapeutics? (NYSE:CATX) - Seeking Alpha

Apr 09, 2025
pulisher
Apr 08, 2025

Perspective Therapeutics (NYSE:CATX) Given New $10.00 Price Target at Truist Financial - Defense World

Apr 08, 2025
pulisher
Apr 07, 2025

Truist cuts Perspective Therapeutics target to $10, maintains Buy By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

Truist cuts Perspective Therapeutics target to $10, maintains Buy - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

Paraganglioma Treatment Market Size in 7MM is expected to grow - openPR.com

Apr 07, 2025
pulisher
Apr 07, 2025

Truist Securities Adjusts Price Target on Perspective Therapeutics to $10 From $21, Keeps Buy Rating - marketscreener.com

Apr 07, 2025
pulisher
Apr 04, 2025

CATX stock touches 52-week low at $1.87 amid market challenges - Investing.com Australia

Apr 04, 2025
pulisher
Apr 04, 2025

CATX stock touches 52-week low at $1.87 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

What is HC Wainwright’s Estimate for CATX Q2 Earnings? - Defense World

Apr 04, 2025
pulisher
Apr 04, 2025

Perspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Rating of “Buy” by Analysts - Defense World

Apr 04, 2025
pulisher
Apr 03, 2025

Pheochromocytoma Treatment Market Size in 7MM is expected - openPR.com

Apr 03, 2025
pulisher
Apr 03, 2025

Pheochromocytomas and Paragangliomas Treatment Market Size - openPR.com

Apr 03, 2025
pulisher
Apr 02, 2025

Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround - Yahoo Finance

Apr 02, 2025
pulisher
Apr 01, 2025

Perspective Therapeutics director Robert Williamson buys $132,151 in stock - Investing.com Australia

Apr 01, 2025
pulisher
Apr 01, 2025

Perspective therapeutics CEO Johan Spoor buys $59,672 in stock - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Perspective Therapeutics director Robert Williamson buys $132,151 in stock By Investing.com - Investing.com Canada

Apr 01, 2025
pulisher
Apr 01, 2025

Perspective Therapeutics CFO Graham Juan acquires $74,945 in stock - Investing.com Australia

Apr 01, 2025
pulisher
Apr 01, 2025

Perspective Therapeutics director Lori Woods acquires $49,999 in stock By Investing.com - Investing.com Canada

Apr 01, 2025
pulisher
Apr 01, 2025

Perspective Therapeutics CFO Graham Juan acquires $74,945 in stock By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

Perspective Therapeutics director Lori Woods acquires $49,999 in stock - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Perspective Therapeutics (NYSE:CATX) Receives "Buy" Rating from HC Wainwright - MarketBeat

Apr 01, 2025
pulisher
Apr 01, 2025

Pharma-Biotech Market Development Analysis Report 2025: Growth Opportunities Shaped by a Convergence of Scientific Innovation, Regulatory Evolution, and Market Pressures - GlobeNewswire Inc.

Apr 01, 2025
pulisher
Apr 01, 2025

Perspective Therapeutics (NYSE:CATX) Given “Buy” Rating at HC Wainwright - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

Perspective Therapeutics to Participate in Upcoming April Investor Conferences - The Manila Times

Mar 31, 2025
pulisher
Mar 31, 2025

Cancer Treatment Innovator Perspective Therapeutics Lines Up Major April Investor Events - Stock Titan

Mar 31, 2025
pulisher
Mar 31, 2025

Swiss National Bank Has $275,000 Stock Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

Research Analysts Issue Forecasts for CATX Q1 Earnings - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

CATX Q1 EPS Forecast Lowered by Brookline Capital Management - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

HighTower Advisors LLC Has $568,000 Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Charles Schwab Investment Management Inc. Sells 26,556 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

Royal Bank of Canada Issues Pessimistic Forecast for Perspective Therapeutics (NYSE:CATX) Stock Price - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

Bank of New York Mellon Corp Grows Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Analysts Offer Insights on Healthcare Companies: Allurion Technologies (ALUR), Perspective Therapeutics (CATX) and Nkarta (NKTX) - The Globe and Mail

Mar 27, 2025
pulisher
Mar 27, 2025

RBC Cuts Price Target on Perspective Therapeutics to $15 From $16, Keeps Outperform, Speculative Risk - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

Perspective Therapeutics earnings missed by $0.37, revenue fell short of estimates - Investing.com Canada

Mar 27, 2025

Finanzdaten der Perspective Therapeutics Inc-Aktie (CATX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
medical_devices ZBH
$97.44
price up icon 1.32%
medical_devices PHG
$24.14
price up icon 3.65%
medical_devices STE
$222.77
price up icon 1.82%
$66.33
price up icon 0.33%
$61.65
price up icon 1.93%
medical_devices EW
$70.60
price up icon 2.02%
Kapitalisierung:     |  Volumen (24h):